Will Eli Lilly reaffirm or raise 2026 revenue guidance citing Zepbound and Foundayo by Nov 13, 2026?
Posted 2026-09-29 — 45 days before the deadline, stated before the outcome.
Eli Lilly is a pharmaceutical company that regularly updates its financial outlook based on the performance of its drug portfolio. Investors monitor these earnings calls for specific data points that influence long-term revenue projections.
The claim
By November 13, 2026, Eli Lilly will release third-quarter 2026 earnings with a full-year 2026 revenue forecast reaffirmed or increased above the level set in August 2026, and management will explicitly cite the Zepbound 15 mg superiority data and new Foundayo results as drivers for the updated or maintained guidance.
Reasoning trace
- Upstream shock: Zepbound (z=6.7); Eli Lilly exposed via 'uses' edge
Evidence so far
0 confirming · 0 denying signals · 0 verified · 0 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 1 time since mint (last on 2026-09-29) — 70% at mint → 79% today.
What to watch
- precondition Eli Lilly files its Form 10-Q for the third quarter of 2026 with the SEC
- leading indicator Eli Lilly publishes the Q3 2026 earnings press release on its investor relations website
- milestone Eli Lilly announces a specific date for its Q3 2026 earnings release and conference call
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.